Skip to main content
SpringerLink
Log in

Hormone Replacement Therapy and the Risk of Cancer in the Breast and Reproductive Organs: A Review of Epidemiological Data

  • Conference paper
HRT and Osteoporosis

  • 89 Accesses

Abstract

Hormone replacement therapy (HRT), by means of oestrogens (and cyclic progestogens), has become recognised as the only well-established prophylactic measure against postmenopausal bone loss [1,2]. Numerous clinical studies have reported a bone-mass preserving effect during study periods extending from 2 to 8 years [3]. Furthermore, the results of several epidemiological studies, of both retrospective and prospective designs, indicate that such treatment can also reduce the risk of fragility fractures in the vertebrae, distal radius and hip [3]. As postmenopausal bone loss, with ensuing bone fragility (osteoporosis), is a major cause of fractures, it has, according to a consensus development conference in 1987 [1], been considered justified to give HRT to women identified to be at increased risk of developing osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Consensus development conference. Prophylaxis and treatment of osteoporosis. Br Med J 1987; 295:914–16.

    Article  Google Scholar 

  2. Editorial. Osteoporosis. Lancet 1987; ii:833–5.

    Google Scholar 

  3. Cummings SR, Kelsey JL, Nevitt MC, O’Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985; 7:178–208.

    PubMed  CAS  Google Scholar 

  4. Peck WA, Riggs BL, Bell NH et al. Scientific workshop: research directions in osteoporosis. Am J Med 1988; 84:275–82.

    Article  PubMed  CAS  Google Scholar 

  5. National Board of Health and Welfare. The Cancer Registry. Cancer Incidence in Sweden 1983. Stockholm 1986.

    Google Scholar 

  6. Waterhouse J, Muir C, Shanmugaratnam K et al., eds. Cancer incidence in five continents, vol IV. IARC, Lyon, 1982.

    Google Scholar 

  7. Adami H-O, Holmberg L, Persson I, Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986; 315:559–63.

    Article  PubMed  CAS  Google Scholar 

  8. Hoover, R, Gray LA, Cole P et al. Menopausal estrogens and breast cancer. N Engl J Med 1976; 295:401–5.

    CAS  Google Scholar 

  9. The Boston Collaborative Drug Surveillance Program. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumours in relation to postmenopausal estrogen therapy. N Engl J Med 1974; 15–18.

    Google Scholar 

  10. Craig TJ, Comstock GW, Geiser PB. Epidemiologic comparison of breast cancer patients with early and late onset of malignancies and general population controls. J Natl Cancer Inst 1974; 53:1577–81.

    PubMed  CAS  Google Scholar 

  11. Casagrande J. Gerkins V, Henderson BE et al. Brief communication: exogenous estrogens and breast cancer in women with natural menopause. J Natl Cancer Inst 1976; 56:839–41.

    PubMed  CAS  Google Scholar 

  12. Sartwell PE, Arthes FG, Tanascia JA. Exogenous estrogens, reproductive history, and breast cancer. J Natl Cancer Inst 1977; 59:1589–92.

    PubMed  CAS  Google Scholar 

  13. Ravnihar B, Seigel DG, Lindtner J. An epidemiological study of breast cancer and benign breast neoplasias in relation to oral contraceptive and estrogen use. Eur J Cancer 1979; 15:395–405.

    Article  PubMed  CAS  Google Scholar 

  14. Jick H, Walker AM, Watkins RN et al. Replacement estrogens and breast cancer. Am J Epidemiol 1980; 112:586–94.

    CAS  Google Scholar 

  15. Ross RK, Paganini-Hill A, Gerkins VR et al. A case-control study of menopausal estrogen therapy and breast cancer. JAMA 1980; 243: 1635–9.

    Article  PubMed  CAS  Google Scholar 

  16. Hoover R, Glass A, Finkle WD et al. Conjugated estrogens and breast cancer risk in women. J Natl Cancer Inst 1981; 67:815–20.

    PubMed  CAS  Google Scholar 

  17. Kelsey JL, Fischer DB, Holford TR et al. Exogenous estrogens and other factors in the epidemiology of breast cancer. J Natl Cancer Inst 1981; 67:327–33.

    PubMed  CAS  Google Scholar 

  18. Brinton LA, Hoover R, Szklo M, Fraumeni JF. Menopausal estrogen use and risk of breast cancer. Cancer 1981; 47:2517–22.

    Article  PubMed  CAS  Google Scholar 

  19. Thomas DB, Pershing JP, Hutchinem WB. Exogenous estrogens and other risk factors for breast cancer in women with benign breast disease. J Natl Cancer Inst 1982; 69:1017–25.

    PubMed  CAS  Google Scholar 

  20. Hulka BS, Chambless LE, Deubner DC, Wilkinson WE. Breast cancer and estrogen replacement therapy. Am J Obstet Gynecol 1982; 638–44.

    Google Scholar 

  21. Hiatt RA, Bawol R, Friedman GD, Hoover R. Exogenous estrogen and breast cancer after bilateral oophorectomy. Cancer 1984; 54:139–44.

    Article  PubMed  CAS  Google Scholar 

  22. Kaufmann DW, Miller DR, Rosenberg L. et al. Noncontraceptive estrogen use and the risk of breast cancer. JAMA 1984; 252:63–7.

    Article  Google Scholar 

  23. Talamini R, La Vecchia C, Franceschi S et al. Reproductive and hormonal factors and breast cancer in a northern Italian population. Int J Epidemiol 1985; 14:70–4.

    Article  PubMed  CAS  Google Scholar 

  24. Brinton LA, Hoover R, Fraumeni JF. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986; 54:825–32.

    Article  PubMed  CAS  Google Scholar 

  25. La Vecchia C, Decarli A, Parazzini F, Gentile A, Liberati C, Franceschi S. Non-contraceptive oestrogens and the risk of breast cancer in women. Int J Cancer 1986; 38:853–58.

    Article  PubMed  Google Scholar 

  26. McDonald I, Weiss N, Daling J, Francis A, Pollisar L. Menopausal estrogen use and the risk of breast cancer. Breast Cancer Res Treat 1986; 7:193–9.

    Article  PubMed  CAS  Google Scholar 

  27. Nomura AMY, Kolonel LN, Hirohata T et al. The association of replacement estrogens with breast cancer. Int J Cancer 1986; 37:49–53.

    Article  PubMed  CAS  Google Scholar 

  28. Wingo PA, Layde PM, Lee NC, Rubin G, Ory HN. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA 1987; 257:209–15.

    Article  PubMed  CAS  Google Scholar 

  29. Buring JE, Hennekens CH, Lipnick RJ et al. A prospective cohort study of postmenopausal hormone use and risk of breast cancer in US women. Am J Epidemiol 1987; 125:939–47.

    PubMed  CAS  Google Scholar 

  30. Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987; 94:620–35.

    Article  PubMed  CAS  Google Scholar 

  31. Ewerts M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988; 42:832–8.

    Google Scholar 

  32. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321:293–7.

    Article  PubMed  CAS  Google Scholar 

  33. Mills PK, Beeson WL, Phillips RL, Fraser GE, Prospective study of exogenous hormone use and breast cancer in Seventh Day Adventists. Cancer 1989; 64:591–7.

    Article  PubMed  CAS  Google Scholar 

  34. Smith DC, Prentice R, Thompson DJ, Herrman WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975; 293:1164–7.

    Article  PubMed  CAS  Google Scholar 

  35. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975; 293:1167–70.

    Article  PubMed  CAS  Google Scholar 

  36. Mack TM, Pike MC, Henderson BE et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976; 294:1262–7.

    Article  PubMed  CAS  Google Scholar 

  37. McDonald TW, Annegers JF, O’Fallon WM, Dockerty MB, Malkasin GD, Kurland LT. Exogenous estrogen and endometrial carcinoma: case-control and incidence study. Am J Obstet Gynecol 1977; 127:572–80.

    PubMed  CAS  Google Scholar 

  38. Gray LA, Christophersen WM, Hoover RN. Estrogens and endometrial carcinoma. Obstet Gynecol 1977; 49:385–9.

    PubMed  Google Scholar 

  39. Antunes CMF, Stolley PD, Rosenshein NB et al. Endometrial cancer and estrogen use. Report of a large case-control study. N Engl J Med 1979; 300:9–13.

    Article  PubMed  CAS  Google Scholar 

  40. Horwitz RI, Feinstein AR. Alternative analytical methods for case-control studies of estrogens and endometrial cancer. N Engl J Med 1978; 299:1089–94.

    Article  PubMed  CAS  Google Scholar 

  41. Weiss NS, Szekely DR, English DR, Schweid AI. Endometrial cancer in relation to patterns of menopausal estrogen use. JAMA 1979; 242:261–4.

    Article  PubMed  CAS  Google Scholar 

  42. Hulka BS, Fowler WC, Kaufman DG et al. Estrogen and endometrial cancer: cases and two control groups from North Carolina. Am J Obstet Gynecol 1980; 137:92–101.

    PubMed  CAS  Google Scholar 

  43. Paganini-Hill A, Ross RK, Henderson BE. Endometrial cancer and patterns of use of estrogen replacement therapy: a cohort study. Br J Cancer 1989; 59:445–7.

    Article  PubMed  CAS  Google Scholar 

  44. Persson I, Adami HO, Bergkvist L et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Br Med J 1989;298:147–51.

    Article  CAS  Google Scholar 

  45. Ziel HK. Estrogen’s role in endometrial cancer. Obstet Gynecol 1982; 60:509–15.

    PubMed  CAS  Google Scholar 

  46. Hulka BS. Effect of exogenous estrogen on postmenopausal women: the epidemiologic evidence. Obstet Gynecol Surv 1980; 35:389–99.

    Article  Google Scholar 

  47. Davies JL, Rosenshein NB, Antunes CMF, Stolley PD. A review of the risk factors for endometrial carcinoma. Obstet Gynecol Surv 1981; 36:107–16.

    Article  PubMed  CAS  Google Scholar 

  48. Collins J, Donner A, Allen LH, Adams O. Oestrogen use and survival in endometrial cancer. Lancet 1980; ii:961–4.

    Article  Google Scholar 

  49. Fox H. Endometrial carcinogenesis and its relation to oestrogens. Pathol Res Pract 1984; 179:13–19.

    Article  PubMed  CAS  Google Scholar 

  50. Whitehead MI, Townsend PT, Pryse-Davies J et al. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981; 305:1599–605.

    Article  PubMed  CAS  Google Scholar 

  51. Ory HW, Layde PM, Webster LA, Wingo PA. Oral contraceptive use and the risk of ovarian cancer. JAMA 1983; 249:1596–9.

    Article  Google Scholar 

  52. Weiss NS, Lyon JL, Liff JM et al. Incidence of ovarian cancer in relation to use of oral contraceptives. Int J Cancer 1981; 28:669–71.

    Article  PubMed  CAS  Google Scholar 

  53. Weiss NS, Lyon JL, Krishnamurthy S et al. Non-contraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 1982; 68:95–8.

    PubMed  CAS  Google Scholar 

  54. Smith EM, Sowers MF, Burns TL. Effects of smoking on the developing of female reproductive cancers. J Natl Cancer Inst 1984; 73:371–6.

    PubMed  CAS  Google Scholar 

  55. Kaufman DW, Kelly JP, Welch WR et al. Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol 1989; 130:1142–51.

    CAS  Google Scholar 

  56. Adami HO, Persson I, Hoover R, Schairer C, Bergkvist, L. The risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989; 44:833–9.

    Article  PubMed  CAS  Google Scholar 

  57. Hartge P, Hoover R, McGowan. et al. Menopause and ovarian cancer. Am J Epidemiol 1988; 127:990–8.

    PubMed  CAS  Google Scholar 

  58. Vessey MP, Lawless M, McPherson K, Yeates D. Neoplasia of the cervix uteri and contraception: a possible adverse effect of the pill. Lancet 1983; ii:930.

    Article  Google Scholar 

Download references

Authors
  1. I. Persson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. O. Adami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Bergkvist
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Clarendon Wing, Leeds General Infirmary, Leeds, LS1 3EX, UK

    James O. Drife MD, FRCS Ed, FRCOG (Professor of Obstetrics and Gynaecology) (Professor of Obstetrics and Gynaecology)

  2. King’s College Hospital, London, SE5 9RS, UK

    John W. W. Studd MD, BS, FRCOG (Consultant Obstetrician and Gynaecologist, Director) (Consultant Obstetrician and Gynaecologist, Director)

  3. The Menopause Clinic, Dulwich Hospital, East Dulwich Grove, London, SE22 8PT, UK

    John W. W. Studd MD, BS, FRCOG (Consultant Obstetrician and Gynaecologist, Director) (Consultant Obstetrician and Gynaecologist, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag London Limited

About this paper

Cite this paper

Persson, I., Adami, H.O., Bergkvist, L. (1990). Hormone Replacement Therapy and the Risk of Cancer in the Breast and Reproductive Organs: A Review of Epidemiological Data. In: Drife, J.O., Studd, J.W.W. (eds) HRT and Osteoporosis. Springer, London. https://doi.org/10.1007/978-1-4471-1799-5_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-1799-5_14

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-1801-5

  • Online ISBN: 978-1-4471-1799-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation